AgingResearch.NewsJoin free
medRxiv

Metformin linked to lower dementia risk in US health records

Metformin’s dementia hazard ratio—a comparison of risk over time—was 0.90 versus sulfonylurea diabetes drugs; the range of likely values included no difference.

Paper by M.-L. Charpignon, T. Shnitzer, A. Iraqui, 2 more authorsC. Uhler · Mit
Brain cross-sections sit beside matching groups of upright people, with fuller dark blue-green folds and wider gaps in the smaller gray section.
Preprint: cohort study of participants starting metformin or sulfonylurea diabetes drugsPopulations

The catch: The dementia risk estimate was compatible with no difference between drugs

Edited by Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

In the National Institutes of Health’s All of Us Research Program, an observational study compared participants starting metformin with those starting sulfonylurea diabetes drugs. The researchers used existing data to emulate a trial rather than randomly assigning drugs. They adjusted for measured differences between groups, including social and behavioral factors, calendar year and earlier diabetes drug use.

Metformin was associated with a dementia hazard ratio of 0.90, although the range of likely values included no difference. It was also linked to a lower risk of death without dementia, with a hazard ratio of 0.61. The findings held across different sets of adjustment factors and when the researchers included participants without a type 2 diabetes diagnosis at the start.

Why it matters

The authors considered metformin a promising candidate for preventing dementia, an age-related condition, and called for prospective validation.

Caveats

This observational analysis could not establish that metformin prevented dementia, and the dementia estimate was compatible with no difference. The report is a preprint and has not been peer-reviewed.

Where the evidence stands

Metformin

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 532 independent labs in 66 countries
  • 241 findings against
  • 1,477 trials, 629 with no results posted
  • Funders: National Institutes of Health and others
  • 172 of 2,453 findings with company ties
  • 195 of 1,477 trials sponsored by its developers

Comments

Be the first to comment.

Metformin is part of Bryan Johnson's Blueprint and David Sinclair's daily regimen in Lifespan

More on Dementia